Pfizer Shares Outstanding 2010-2024 | PFE
Pfizer shares outstanding history from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Pfizer shares outstanding for the quarter ending September 30, 2024 were 5.705B, a 1.04% increase year-over-year.
- Pfizer 2023 shares outstanding were 5.709B, a 0.42% decline from 2022.
- Pfizer 2022 shares outstanding were 5.733B, a 0.44% increase from 2021.
- Pfizer 2021 shares outstanding were 5.708B, a 1.35% increase from 2020.
Pfizer Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
5,709 |
| 2022 |
5,733 |
| 2021 |
5,708 |
| 2020 |
5,632 |
| 2019 |
5,675 |
| 2018 |
5,977 |
| 2017 |
6,058 |
| 2016 |
6,159 |
| 2015 |
6,257 |
| 2014 |
6,424 |
| 2013 |
6,895 |
| 2012 |
7,508 |
| 2011 |
7,870 |
| 2010 |
8,074 |
| 2009 |
7,045 |
Pfizer Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-09-30 |
5,705 |
| 2024-06-30 |
5,696 |
| 2024-03-31 |
5,697 |
| 2023-12-31 |
5,709 |
| 2023-09-30 |
5,646 |
| 2023-06-30 |
5,713 |
| 2023-03-31 |
5,727 |
| 2022-12-31 |
5,733 |
| 2022-09-30 |
5,718 |
| 2022-06-30 |
5,712 |
| 2022-03-31 |
5,758 |
| 2021-12-31 |
5,708 |
| 2021-09-30 |
5,725 |
| 2021-06-30 |
5,678 |
| 2021-03-31 |
5,662 |
| 2020-12-31 |
5,632 |
| 2020-09-30 |
5,633 |
| 2020-06-30 |
5,619 |
| 2020-03-31 |
5,613 |
| 2019-12-31 |
5,675 |
| 2019-09-30 |
5,649 |
| 2019-06-30 |
5,672 |
| 2019-03-31 |
5,750 |
| 2018-12-31 |
5,977 |
| 2018-09-30 |
5,986 |
| 2018-06-30 |
5,952 |
| 2018-03-31 |
6,057 |
| 2017-12-31 |
6,058 |
| 2017-09-30 |
6,041 |
| 2017-06-30 |
6,037 |
| 2017-03-31 |
6,092 |
| 2016-12-31 |
6,159 |
| 2016-09-30 |
6,150 |
| 2016-06-30 |
6,149 |
| 2016-03-31 |
6,225 |
| 2015-12-31 |
6,257 |
| 2015-09-30 |
6,243 |
| 2015-06-30 |
6,243 |
| 2015-03-31 |
6,292 |
| 2014-12-31 |
6,424 |
| 2014-09-30 |
6,403 |
| 2014-06-30 |
6,444 |
| 2014-03-31 |
6,476 |
| 2013-12-31 |
6,895 |
| 2013-09-30 |
6,656 |
| 2013-06-30 |
7,117 |
| 2013-03-31 |
7,269 |
| 2012-12-31 |
7,508 |
| 2012-09-30 |
7,508 |
| 2012-06-30 |
7,537 |
| 2012-03-31 |
7,598 |
| 2011-12-31 |
7,870 |
| 2011-09-30 |
7,810 |
| 2011-06-30 |
7,935 |
| 2011-03-31 |
8,035 |
| 2010-12-31 |
8,074 |
| 2010-09-30 |
8,057 |
| 2010-06-30 |
8,072 |
| 2010-03-31 |
8,101 |
| 2009-12-31 |
7,045 |
| 2009-09-30 |
6,762 |
| 2009-06-30 |
6,752 |
| 2009-03-31 |
6,753 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$146.038B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
